stoxline Quote Chart Rank Option Currency Glossary
  
NovaBay Pharmaceuticals, Inc. (NBY)
0.663  0.013 (2%)    07-18 16:00
Open: 0.7
High: 0.7
Volume: 15,680
  
Pre. Close: 0.65
Low: 0.6482
Market Cap: 4(M)
Technical analysis
2025-07-18 4:43:11 PM
Short term     
Mid term     
Targets 6-month :  0.87 1-year :  1.02
Resists First :  0.75 Second :  0.87
Pivot price 0.64
Supports First :  0.63 Second :  0.56
MAs MA(5) :  0.66 MA(20) :  0.62
MA(100) :  0.59 MA(250) :  0.62
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  44 D(3) :  48.3
RSI RSI(14): 58.3
52-week High :  2.25 Low :  0.36
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ NBY ] has closed below upper band by 35.5%. Bollinger Bands are 15.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.7 - 0.7 0.7 - 0.71
Low: 0.64 - 0.64 0.64 - 0.65
Close: 0.66 - 0.66 0.66 - 0.67
Company Description

NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

Headline News

Fri, 18 Jul 2025
What drives NovaBay Pharmaceuticals Inc. stock price - Explosive returns - Jammu Links News

Fri, 07 Mar 2025
NovaBay Pharmaceuticals to Hold Special Meeting of Stockholders - Business Wire

Thu, 23 Jan 2025
NovaBay Pharmaceuticals Completes the Sale of its Eyecare Business to PRN and Further Adjourns its Special Meeting of Stockholders on Dissolution Proposal - Business Wire

Wed, 25 Dec 2024
NovaBay Pharmaceuticals (NBY) Upgraded to Buy: Here's Why - Yahoo Finance

Fri, 15 Nov 2024
User - FinancialContent

Wed, 06 Nov 2024
NovaBay accepts higher PRN offer, says Refresh deal no longer superior (NYSE:NBY) - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
AMEX
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 5 (M)
Shares Float 5 (M)
Held by Insiders 0 (%)
Held by Institutions 0.2 (%)
Shares Short 136 (K)
Shares Short P.Month 32 (K)
Stock Financials
EPS -76.05
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.47
Profit Margin -76.9 %
Operating Margin -43.9 %
Return on Assets (ttm) -32.8 %
Return on Equity (ttm) -283 %
Qtrly Rev. Growth -32.1 %
Gross Profit (p.s.) 0
Sales Per Share 2.83
EBITDA (p.s.) -1.03
Qtrly Earnings Growth 0 %
Operating Cash Flow -3 (M)
Levered Free Cash Flow 2 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value -1.45
Price to Sales 0.23
Price to Cash Flow -1.07
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android